Status
Conditions
Treatments
About
This is a parallel group, multisite prospective clinical study. The purpose of this study is to evaluate whether ASCENT enables patients to adhere to the survivorship guidelines and improves coordination of care to address patient needs.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Histologically confirmed diagnosis of prostate adenocarcinoma
Age ≥18 years
Receiving curative intent radiotherapy for prostate cancer (Note: post-operative radiotherapy [i.e., "adjuvant" or "salvage radiotherapy subsequent to prostatectomy] is allowed.)
Subjects will be enrolled within two weeks prior to and two weeks after the final fraction of radiotherapy.
Receiving androgen deprivation therapy (ADT) for a duration of ≥3 consecutive months as follows:
Technology requirement: candidates must have access to the internet
Able to understand and willing to sign a written informed consent document.
Able to speak and understand English, in the opinion of the treating physician.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
77 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal